Clinical trial

New Onset Type 1 Diabetes: Role of Exenatide

NCT01269034

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2010-12-01

PhasePHASE4

Study timeline

Study start (unknown)2010-12-01Date precision: month

Registry last updated2021-08-04

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 1 Diabetesunresolved

Interventions

ExenatideDRUG · verified · RxNorm: exenatide

Rapid and long acting insulinDRUG

long acting insulin + rapid acting + 1.25 mcg ExenatideDRUG

Sponsors & collaborators

Albert Einstein College of Medicinelead sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)collaborator

Mapped research locations

The BronxNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01269034 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.